Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Storage bufferpH: 7.30
Preservative: 0.02% Sodium azide
Constituents: 0.05% Tris, 0.5% BSA
Concentration information loading...
PurityImmunogen affinity purified
Purification notesPurified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Immunizing Peptide (Blocking)
Our Abpromise guarantee covers the use of ab2230 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 1 - 4 µg/ml. Predicted molecular weight: 51 kDa.Can be blocked with Human BLNK peptide (ab22871).
Approx 70kDa band seen in Daudi lysate.
FunctionFunctions as a central linker protein that bridges kinases associated with the B-cell receptor (BCR) with a multitude of signaling pathways, regulating biological outcomes of B-cell function and development. Plays a role in the activation of ERK/EPHB2, MAP kinase p38 and JNK. Modulates AP1 activation. Important for the activation of NF-kappa-B and NFAT. Plays an important role in BCR-mediated PLCG1 and PLCG2 activation and Ca(2+) mobilization and is required for trafficking of the BCR to late endosomes. However, does not seem to be required for pre-BCR-mediated activation of MAP kinase and phosphatidyl-inositol 3 (PI3) kinase signaling. May be required for the RAC1-JNK pathway. Plays a critical role in orchestrating the pro-B cell to pre-B cell transition (By similarity). Plays an important role in BCR-induced B-cell apoptosis.
Tissue specificityExpressed in B-cell lineage and fibroblast cell lines (at protein level). Highest levels of expression in the spleen, with lower levels in the liver, kidney, pancreas, small intestines and colon.
Involvement in diseaseDefects in BLNK are the cause of agammaglobulinemia type 4 (AGM4) [MIM:613502]. It is a primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B cells due to an early block of B-cell development. Affected individuals develop severe infections in the first years of life.
Sequence similaritiesContains 1 SH2 domain.
modificationsFollowing BCR activation, phosphorylated on tyrosine residues by SYK and LYN. When phosphorylated, serves as a scaffold to assemble downstream targets of antigen activation, including PLCG1, VAV1, GRB2 and NCK1. Phosphorylation of Tyr-84, Tyr-178 and Tyr-189 facilitates PLCG1 binding. Phosphorylation of Tyr-96 facilitates BTK binding. Phosphorylation of Tyr-72 facilitates VAV1 and NCK1 binding. Phosphorylation is required for both Ca(2+) and MAPK signaling pathways.
Cellular localizationCytoplasm. Cell membrane. BCR activation results in the translocation to membrane fraction.
- Information by UniProt
- AGM4 antibody
- B cell adapter containing SH2 domain protein antibody
- B cell adapter containing Src homology 2 domain protein antibody
Anti-BLNK antibody (ab2230) at 4 µg/ml + Cell lysate prepared from human Daudi cells at 35 µg
Developed using the ECL technique.
Predicted band size: 51 kDa
Observed band size: 70 kDa why is the actual band size different from the predicted?
Ab2230 staining (4
µg/ml) of Daudi lysate (RIPA buffer, 30 µg total protein per lane). Primary incubated for 1 hour. Detected by western blot using chemiluminescence Primary incubated for 1 hour.
All lanes : Anti-BLNK antibody (ab2230) at 1 µg/ml
Lane 1 : Cell lysate prepared from HEK293 mock transfected cells
Lane 2 : Cell lysate prepared from HEK293 overexpressing BLNK
Predicted band size: 51 kDa
Observed band size: 50 kDa why is the actual band size different from the predicted?
ab2230 has not yet been referenced specifically in any publications.